Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Derek-Zhen Xu"'
Autor:
Colby S. Shemesh, Phyllis Chan, Hui Shao, Derek-Zhen Xu, Daniel Combs, Shweta Vadhavkar, René Bruno, Benjamin Wu
Publikováno v:
Liver Cancer, Pp 373-387 (2021)
Introduction: Phase 1b GO30140 and phase 3 IMbrave150 studies evaluated first-line atezolizumab + bevacizumab for unresectable hepatocellular carcinoma (HCC). Here, we evaluated pharmacokinetics (PK) and safety by hepatic impairment status and geogra
Externí odkaz:
https://doaj.org/article/f8d45bc5536d4dbea12b123bae4808b0
Autor:
Shukui Qin, Zhenggang Ren, Yin-Hsun Feng, Thomas Yau, Baocheng Wang, Haitao Zhao, Yuxian Bai, Shanzhi Gu, Lindong Li, Sairy Hernandez, Derek-Zhen Xu, Sohail Mulla, Yifan Wang, Hui Shao, Ann Lii Cheng
Publikováno v:
Liver Cancer, Pp 1-13 (2021)
Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety data from th
Externí odkaz:
https://doaj.org/article/8419d086468a48ccade95457dd922afe
Autor:
Phyllis Chan, Benjamin Wu, Colby S. Shemesh, Shweta Vadhavkar, Derek-Zhen Xu, Daniel Combs, Rene Bruno, Hui Shao
Publikováno v:
Liver Cancer, Pp 373-387 (2021)
Liver Cancer
Liver Cancer
Introduction: Phase 1b GO30140 and phase 3 IMbrave150 studies evaluated first-line atezolizumab + bevacizumab for unresectable hepatocellular carcinoma (HCC). Here, we evaluated pharmacokinetics (PK) and safety by hepatic impairment status and geogra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c21240fb961b51f4ee18362d130dd5f
https://www.karger.com/Article/FullText/515817
https://www.karger.com/Article/FullText/515817
Autor:
S. Mulla, Yin-Hsun Feng, Ann-Lii Cheng, Yifan Wang, Shukui Qin, Sairy Hernandez, Lindong Li, Yuxian Bai, Baocheng Wang, Shanzhi Gu, Thomas Yau, Haitao Zhao, Zhenggang Ren, Hui Shao, Derek-Zhen Xu
Publikováno v:
Liver Cancer, Pp 1-13 (2021)
Liver Cancer
Liver Cancer
Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety data from th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::995bd18d450c8713ef9f561db8c4ebf3
https://www.karger.com/Article/FullText/513486
https://www.karger.com/Article/FullText/513486
Autor:
Ye Guo, Aflah Roohullah, Junli Xue, Wei Zhao, Morteza Aghmesheh, David Martin, Yu Zhou, Chao Gao, Yixuan Yang, Derek-Zhen Xu, Jin Li
Publikováno v:
Cancer Research. 82:6180-6180
Background: SCB-313 is a recombinant human TRAIL-Trimer™ fusion protein engineered using a stabilized trimeric form of the TRAIL-protein. Binding of SCB-313 to the death receptors 4 and 5 leads to the activation of the extrinsic apoptosis pathway.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c797a34b614aebeef25ae5bc378bf55
https://doi.org/10.1158/1538-7445.am2022-6180
https://doi.org/10.1158/1538-7445.am2022-6180
Autor:
Valeriy Breder, Beiying Ding, Andrew X. Zhu, Daneng Li, Ann-Lii Cheng, Richard S. Finn, Tae-You Kim, Ahmed Kaseb, Masafumi Ikeda, Philippe Merle, S. Mulla, Chen Huang, Juan Liu, Shukui Qin, Masatoshi Kudo, Peter R. Galle, Michel Ducreux, Wendy Verret, Derek Zhen Xu, Sairy Hernandez, Ho Yeong Lim
Publikováno v:
The Lancet. Oncology. 22(7)
Summary Background Understanding patients' experience of cancer treatment is important. We aimed to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3267d98f7949fd7d881cf93f82220fa
https://pubmed.ncbi.nlm.nih.gov/34051881
https://pubmed.ncbi.nlm.nih.gov/34051881
Autor:
Derek-Zhen Xu, Tae-You Kim, Juan Liu, Andrew X. Zhu, Michel Ducreux, Ho Yeong Lim, Peter R. Galle, Valeriy Breder, Masafumi Ikeda, Wendy Verret, Masatoshi Kudo, Richard S. Finn, Philippe Merle, IMbrave Investigators, Chen Huang, Shukui Qin, Sairy Hernandez, Daneng Li, Ann-Lii Cheng, Yulei Wang, Sohail M. Mulla, Ahmed O Kaseb
Publikováno v:
The New England journal of medicine. 382(20)
The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma.In a global, open-label, phase 3 trial, patients with unresectable hepa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8e9d17b74bb87e87c8e481b1a0ca5c3
https://pubmed.ncbi.nlm.nih.gov/33422270
https://pubmed.ncbi.nlm.nih.gov/33422270
Autor:
Derek-Zhen Xu, Sairy Hernandez, Daneng Li, Valeriy Breder, Ann-Lii Cheng, Ahmed Kaseb, Ho Yeong Lim, Richard S. Finn, Shukui Qin, Masafumi Ikeda, Philippe Merle, Tae-You Kim, Masatoshi Kudo, Michel Ducreux, Peter R. Galle, Yin-Hsun Feng, Beiying Ding, Wendy Verret, Andrew X. Zhu
Publikováno v:
Journal of Clinical Oncology. 38:4596-4596
4596 Background: In the Phase III IMbrave150 trial, statistically significant and clinically meaningful improvements in OS and PFS were seen with atezo + bev vs sor in pts with unresectable HCC who had not received prior systemic therapy (Cheng, ESMO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae2c59107938b7d0ee197f63df8b45f7
https://doi.org/10.1200/jco.2020.38.15_suppl.4596
https://doi.org/10.1200/jco.2020.38.15_suppl.4596
Autor:
Derek-Zhen Xu, Ann-Lii Cheng, Juan Liu, Masatoshi Kudo, Shukui Qin, Masafumi Ikeda, Philippe Merle, Richard S. Finn, Valeriy Breder, Wendy Verret, Ahmed Kaseb, Sohail Mulla, Michel Ducreux, Chen Huang, Daneng Li, Tae-You Kim, Peter R. Galle, Andrew X. Zhu, Sairy Hernandez, Ho Yeong Lim
Publikováno v:
Journal of Clinical Oncology. 38:476-476
476 Background: Atezo + bev in pts with unresectable HCC who had not received prior systemic therapy has shown statistically significant and clinically meaningful improvement in OS and PFS per independent review facility-assessed RECIST 1.1 vs sor in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d8f0b51a887084afbb692cc64c23554
https://doi.org/10.1200/jco.2020.38.4_suppl.476
https://doi.org/10.1200/jco.2020.38.4_suppl.476
Autor:
S. Qin, Andrew X. Zhu, Michel Ducreux, Tae Yong Kim, Masafumi Ikeda, Peter R. Galle, Juan Liu, Derek-Zhen Xu, Wendy Verret, Richard S. Finn, A-L Cheng
Publikováno v:
Annals of Oncology. 29:ix66
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70f47d5fa3cc80a11ea2e6918bcd132c
https://doi.org/10.1093/annonc/mdy432.060
https://doi.org/10.1093/annonc/mdy432.060